

## Company Overview

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.

## BioXcel Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021

Oct 27 2021, 7:00 AM EDT

## BioXcel Therapeutics Announces Expansion of Phase 2 Trial of BXCL701 in De Novo and Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer

Oct 18 2021, 7:00 AM EDT

## BioXcel Therapeutics to Highlight Novel Approaches in AI-Based Drug Candidate Discovery and Development and Advances in Neuroscience Portfolio at Virtual R&D Day

Sep 23 2021, 7:00 AM EDT

## Stock Overview

|            |                   |  |
|------------|-------------------|--|
| Symbol     | BTAI              | FTI Consulting   |
| Exchange   | Nasdaq            | Matt Ventimiglia   |
| Market Cap | 427.62m           | T: 212-850-5624  |
| Last Price | \$15.26           | <a href="mailto:matthew.ventimiglia@fticonsulting.com">matthew.ventimiglia@fticonsulting.com</a> |
| 52-Week    | \$8.795 - \$36.49 |  |

08/15/2022 04:00 PM EDT

## Investor Relations

## Management Team

### Vimal Mehta, Ph.D.

Chief Executive Officer & Founder

### Richard I. Steinhart

Chief Financial Officer & Vice President

### Frank D. Yocca, Ph.D.

Chief Scientific Officer

### Vincent J.O'Neill M.D.

Senior Vice President & Chief Medical Officer

### Javier Rodriguez

Senior Vice President, Chief Legal Officer, and Corporate Secretary

## BioXcel Therapeutics, Inc.

555 Long Wharf Drive  
12th Floor  
New Haven, CT 06511  
United States

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.